3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
24
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Biochemically Recurrent Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
28
Rituximab
23
fludarabine
14
fludarabine phosphate
12
Specimen Handling
11
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Prednisone
8
Doxorubicin
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Whole-Body Irradiation
7
Phantoms, Imaging
7
Mycophenolic Acid
7
Etoposide
7
Biopsy
7
venetoclax
6
glofitamab
6
Melphalan
6
Lenalidomide
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
darolutamide
×
90 days
×
Clear all
No trials found.